| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000737 | Dna catabolic process, endonucleolytic | Increases phenotype | PMID:35521929 |
| GO:0002523 | Leukocyte migration involved in inflammatory response | Increases phenotype | PMID:34665902 |
| GO:0003954 | Nadh dehydrogenase activity | Decreases phenotype | PMID:26721194 |
| GO:0004111 | Creatine kinase activity | Affects phenotype | PMID:26721194; PMID:30243740 |
| GO:0004364 | Glutathione transferase activity | Decreases phenotype | PMID:26680107 |
| GO:0004448 | Isocitrate dehydrogenase [nad(p)+] activity | Decreases phenotype | PMID:26721194 |
| GO:0004457 | Lactate dehydrogenase activity | Increases phenotype | PMID:26721194 |
| GO:0004602 | Glutathione peroxidase activity | Decreases phenotype | PMID:26680107; PMID:26721194; PMID:26996544 |
| GO:0004784 | Superoxide dismutase activity | Affects phenotype | PMID:26680107; PMID:26721194; PMID:34171690; PMID:35521929 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:26801986; PMID:34171690; PMID:35521929 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:26680107; PMID:26721194; PMID:26996544 |
| GO:0006754 | Atp biosynthetic process | Decreases phenotype | PMID:26721194 |
| GO:0007254 | Jnk cascade | Increases phenotype | PMID:30048646 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:26801986; PMID:9164984 |
| GO:0010189 | Vitamin e biosynthetic process | Decreases phenotype | PMID:26680107; PMID:26996544 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:26680107; PMID:26721194; PMID:26996544; PMID:30243740; PMID:35521929 |
| GO:0016615 | Malate dehydrogenase activity | Decreases phenotype | PMID:26721194 |
| GO:0019432 | Triglyceride biosynthetic process | Increases phenotype | PMID:26680107; PMID:26721194 |
| GO:0019853 | L-ascorbic acid biosynthetic process | Decreases phenotype | PMID:26680107; PMID:26996544 |
| GO:0032148 | Activation of protein kinase b activity | Increases phenotype | PMID:30048646 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:106178 |
| GO:0042756 | Drinking behavior | Affects phenotype | PMID:34665902 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:35521929 |
| GO:0045429 | Positive regulation of nitric oxide biosynthetic process | Increases phenotype | PMID:36535314 |
| GO:0045672 | Positive regulation of osteoclast differentiation | Increases phenotype | PMID:30048646 |
| GO:0045780 | Positive regulation of bone resorption | Increases phenotype | PMID:30048646 |
| GO:0046466 | Membrane lipid catabolic process | Increases phenotype | PMID:26801986 |
| GO:0055088 | Lipid homeostasis | Affects phenotype | PMID:36535314 |
| GO:0061370 | Testosterone biosynthetic process | Affects phenotype | PMID:34171690 |
| GO:0061726 | Mitochondrion disassembly | Increases phenotype | PMID:26721194 |
| GO:0070328 | Triglyceride homeostasis | Affects phenotype | PMID:36535314 |
| GO:0070994 | Detection of oxidative stress | Increases phenotype | PMID:34171690; PMID:34665902 |
| GO:0071848 | Positive regulation of erk1 and erk2 cascade via tnfsf11-mediated signaling | Increases phenotype | PMID:30048646 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:35521929 |
| GO:0097722 | Sperm motility | Decreases phenotype | PMID:34171690 |
| GO:1901670 | Negative regulation of superoxide dismutase activity | Increases phenotype | PMID:26801986 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:30243740 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:36535314 |
| GO:1905665 | Positive regulation of calcium ion import across plasma membrane | Increases phenotype | PMID:28945920 |
| GO:2000786 | Positive regulation of autophagosome assembly | Increases phenotype | PMID:36535314 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.